Business
Press Release May 20 2026
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 20, 2026, titled "Ichnos Glenmark Innovation (IGI) Announces New Development Candidate, ISB 2301, a First-in-Class Multispecific Immune Cells Activator Targeting Solid Tumors".
About this update from Glenmark Pharmaceuticals Limited
[{"type":"text","content":" Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 20, 2026, titled \"Ichnos Glenmark Innovation (IGI) Announces New Development Candidate, ISB 2301, a First-in-Class Multispecific Immune Cells Activator Targeting Solid Tumors\". View Attachment","length":422,"tagName":"div"}]